Integrated genome and tissue engineering enables screening of cancer vulnerabilities in physiologically relevant perfusable ex vivo cultures. (January 2022)

• Record Type: Journal Article
• Authors: Hu, Michael; Lei, Xin Yi; Larson, Jon D.; McAlonis, Melissa; Ford, Kyle; McDonald, Daniella; Mach, Krystal; Rusert, Jessica M.; Wechsler-Reya, Robert J.; Mali, Prashant
• Is Part Of: Biomaterials. Volume 280(2022)
• Publication Date: 2022-01
• Subjects: Bioprinting -- Breast cancer model -- Medulloblastoma model -- CRISPR screens -- Point-of-care functional screens; Biomedical materials -- Periodicals; Biocompatible Materials -- Periodicals; Biomatériaux -- Périodiques; 610.28
• DOI: 10.1016/j.biomaterials.2021.121276
• Languages: English
• ISSNs: 0142-9612

Abstract

Abstract: Genetic screens are powerful tools for both resolving biological function and identifying potential therapeutic targets, but require physiologically accurate systems to glean biologically useful information. Here, we enable genetic screens in physiologically relevant ex vivo cancer tissue models by integrating CRISPR-Cas-based genome engineering and biofabrication technologies. We first present a novel method for generating perfusable tissue constructs, and validate its functionality by using it to generate three-dimensional perfusable dense cultures of cancer cell lines and sustain otherwise ex vivo unculturable patient-derived xenografts. Using this system we enable large-scale CRISPR screens in perfused tissue cultures, as well as emulate a novel point-of-care diagnostics scenario of a clinically actionable CRISPR knockout (CRISPRko) screen of genes with FDA-approved drug treatments in ex vivo PDX cell cultures. Our results reveal differences across in vitro and in vivo cancer model systems, and highlight the utility of programmable tissue engineered models for screening therapeutically relevant cancer vulnerabilities.